Frequency of <scp>C</scp>lass <scp>I</scp> and <scp>II HLA</scp> alleles in patients with lung cancer according to chemotherapy response and 5‐year survival

Araz, Ömer; Uçar, Elif Yılmazel; Meral, Mehmet; Yalçin, Aslıhan; Acemoğlu, Hamit; Doğan, Hasan Serkan; Karaman, Adem; Aydın, Yener; Görgüner, Metin; Akgün, Metin

doi:10.1111/crj.12143

Cited by 12 publications

(10 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…And HLA-DRB1*07 was significantly higher in patients at an early stage than those at an advanced stage 37. Omer Araz et al found NSCLC patients who had better response to gemcitabine and cisplatin combination chemotherapy regimen had significantly higher frequency of HLA-DRB1*13, HLA-DQ5, HLA-DQ7 38…”

Section: Encoding Gene Of Mhc Class II and Nsclcmentioning

confidence: 98%

Major histocompatibility complex class II molecule in non-small cell lung cancer diagnosis, prognosis and treatment

Wang

Zhao

Zhang

et al. 2019

OTT

View full text Add to dashboard Cite

Lung cancer is one of the commonest cancers in the world. More than 70% of lung cancer patients are diagnosed with non-small cell lung cancer (NSCLC). Major histocompatibility complex class II (MHC class II), an important component in antigen presenting process, usually expresses on professional antigen presenting cells (APCs), and it can be induced by interferon-γ (IFN-γ). MHC class II can be expressed by NSCLC cells. In NSCLC patients, the expression of MHC class II can be correlated with the outcome of anti-programmed death-1 (anti-PD-1) therapy. This review summarizes MHC class II expression in NSCLC and the correlation between MHC class II and NSCLC diagnosis, prognosis and therapy.

show abstract

Section: Encoding Gene Of Mhc Class II and Nsclcmentioning

confidence: 98%

Major histocompatibility complex class II molecule in non-small cell lung cancer diagnosis, prognosis and treatment

Wang

Zhao

Zhang

et al. 2019

OTT

View full text Add to dashboard Cite

show abstract

“…Lung cancer is one of the most common malignant tumours in humans, causing many deaths every year [ 80 , 81 ]. The 5-year survival rate of lung cancer patients is still very low despite continuous improvement and progress in the diagnosis and treatment of lung cancer [ 82 , 83 ]. Non-small-cell lung carcinoma (NSCLC) accounts for 85% of all pathological types of lung cancer [ 82 , 83 ].…”

Section: Introductionmentioning

confidence: 99%

“…The 5-year survival rate of lung cancer patients is still very low despite continuous improvement and progress in the diagnosis and treatment of lung cancer [ 82 , 83 ]. Non-small-cell lung carcinoma (NSCLC) accounts for 85% of all pathological types of lung cancer [ 82 , 83 ]. Our attention should be focused on the abnormal molecular biological characteristics of NSCLC to find an effective treatment.…”

Section: Introductionmentioning

confidence: 99%

Novel insights on m6A RNA methylation in tumorigenesis: a double-edged sword

et al. 2018

View full text Add to dashboard Cite

N6-methyladenosine (m6A), the most prevalent modification of mammalian RNA, has received increasing attention. Although m6A has been shown to be associated with biological activities, such as spermatogenesis modulation, cell spermatogenesis and pluripotency, Drosophila sex determination, and the control of T cell homeostasis and response to heat shock, little is known about its roles in cancer biology and cancer stem cells. Recent articles have noted that some genes have abnormal m6A expression after tumorigenesis, including genes ABS2, RARA, MYB, MYC, ADAM19 and FOX1. Abnormal changes in the m6A levels of these genes are closely related to tumour occurrence and development. In this review, we summarized the ‘dual edge weapon’ role of RNA methylation in the tumorigenesis. We discussed RNA methylation could lead to not only tumour progression but also tumour suppression. Moreover, we clarified that the abnormal changes in the m6A enrichment of specific loci contribute to tumour occurrence and development, thereby representing a novel anti-cancer strategy by restoration to balanced RNA methylation in tumour cells.

show abstract

“…3,4 Due to the high metastasis and chemoresistance, the 5-year survival rate of NSCLC patients remains dismal. 5,6 It is urgently needed to identify novel effective early diagnostic markers and therapeutic targets.…”

Section: Introductionmentioning

confidence: 99%

Circ_SATB2 Attenuates the Anti-Tumor Role of Celastrol in Non-Small-Cell Lung Carcinoma Through Targeting miR-33a-5p/E2F7 Axis

Liu¹,

Wang²,

Tang³

et al. 2020

OTT

View full text Add to dashboard Cite

Frequency of Class I and II HLA alleles in patients with lung cancer according to chemotherapy response and 5‐year survival

Abstract: Our results suggested that expressions of HLA-BW6 and HLA-DRB1*13 alleles may be predictable markers for response to chemotherapy in lung cancer patients.

Cited by 12 publications

References 35 publications

<p>Major histocompatibility complex class II molecule in non-small cell lung cancer diagnosis, prognosis and treatment</p>

<p>Major histocompatibility complex class II molecule in non-small cell lung cancer diagnosis, prognosis and treatment</p>

Novel insights on m6A RNA methylation in tumorigenesis: a double-edged sword

<p>Circ_SATB2 Attenuates the Anti-Tumor Role of Celastrol in Non-Small-Cell Lung Carcinoma Through Targeting miR-33a-5p/E2F7 Axis</p>

Contact Info

Product

Resources

About